
An expert rheumatologist shares key insights into common causes, typical presentation, and differential diagnosis of systemic lupus erythematous (SLE) and idiopathic inflammatory myopathies.

An expert rheumatologist shares key insights into common causes, typical presentation, and differential diagnosis of systemic lupus erythematous (SLE) and idiopathic inflammatory myopathies.

Rheumatology Network sat down with Pedro Machado, MD, PhD, to discuss his EULAR 2021 presentation entitled, “COVID-19 vaccine safety in patients with rheumatic and musculoskeletal disease.”

Kostas N. Botsoglou, MD, provides an overview of systemic autoimmune rheumatic diseases (SARDs) or connective tissue diseases by discussing their overall characteristics, common comorbidities, and impact on patient quality of life.

Roy Fleischmann, MD, discusses his presentations for EULAR 2021, which include topics about the side effects of JAK inhibitors, disease activity measures of methotrexate withdrawal among patients with rheumatoid arthritis, and the long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis.

Neil Solomons, MD, sits down to discuss his latest study, entitled “Aurinia Announces Publication of AURORA 1 Phase 3 Study Results with LUPKYNIS™ (voclosporin) in The Lancet,” which will be presented at EULAR 2021.

As a part of our EULAR 2021 coverage, Rheumatology Network sat down with John Botson, MD, RPh, CCD, to discuss why patients with uncontrolled gout are significantly burdened with systemic co-morbid disease, why gout is more prevalent and severe in patients who have received kidney transplants, and why such few studies have been published on the use of pegloticase in organ transplant patients.

Rheumatology Network interviewed Laura Coates, MBChB, MRCP, PhD, to discuss what her recent study adds to existing psoriatic arthritis (PsA) research, what some of the key factors are that impact a patient’s opinion of remission, and the clinical significance.

Rheumatology Network sat down with Daniel Hernandez, MD, and Shilpa Venkatachalam, PhD, MPH, of CreakyJoints to highlight health disparities in marginalized communities and introduce their exciting new venture, CreakyJoints Espanol.

This week, Rheumatology Network sat down with Philip J. Mease, MD, to discuss his study, “Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis.”

Recommendations for supporting patients with psoriatic arthritis in the primary care setting and guidance on referring patients to a specialist.

Circumstances that may warrant a switch in therapy to either a similar drug or a drug of a different class.

Currently available non-biologic and biologic therapies used to treat psoriatic arthritis and guidance regarding proper treatment selection and use.

Goals of therapy and considerations that need to be factored into treatment decisions for patients with psoriatic arthritis.

An overview of the clinical manifestations of psoriatic arthritis and recommendations for properly assessing patient symptoms when measuring disease severity.

Strategies that can help clinicians assess patients with psoriatic arthritis for signs of disease progression.

The impact of psoriatic arthritis on patients’ quality of life and importance of an early, accurate diagnosis.

Rheumatology Network sat down with Rebecca Manno, MD, MHS, to discuss the American College of Rheumatology State of the Art (ACR SOTA) Clinical Symposium, which ran from April 9-11.

As a part of our partnership with CreakyJoints, Rheumatology Network sat down with Lauren Gelman, Director of Editorial Services, for the Global Healthy Living Foundation. CreakyJoints is a support, education, advocacy, and research organization for people living with arthritis and rheumatic disease.

This week, Rheumatology Network sat down Brad Marder, MD, co-author of the study, Pegloticase Therapy in Gout Patients Undergoing Dialysis: A USRDS Database Study. Data suggests that pegloticase is successful in the treatment of dialysis patients with uncontrolled gout with potentially lower ESA dose requirements after treatment.

This week, Rheumatology Network sat down with Daniel J. Lovell, MD, MPH, to discuss his study, “Prevalence of autoimmune diseases and other associated conditions in children and young adults with juvenile idiopathic arthritis.”

In this video, Jack March, a physiotherapist specializing in rheumatology, demonstrates exercises for rheumatoid arthritis (RA) relief. He discusses providing exercises for patients, how to prescribe them, reasons to get patients to exercise, and the many benefits that come from engaging in a workout routine.

This week, Rheumatology Network sat down to interview S. Louis Bridges, MD, PhD, to highlight the availability of funds for projects exploring telehealth. Bridges is the President of the Rheumatology Research Foundation, as well as Physician-in-Chief and Chair of the Department of Medicine at the Hospital for Special Surgery (HSS), as well as Chief of the Division of Rheumatology at HSS and Weill Cornell College of Medicine.

Pegloticase in conjunction with immunomodulator combination therapy significantly increased pegloticase responder rates when compared with pegloticase monotherapy for patients with uncontrolled or refractory gout, according to a study. This week, Rheumatology Network interviewed lead investigator, Robert Keenan, MD, to discuss his findings.

Brian Skaggs, PhD, and Maureen McMahon, MD, sat down with Rheumatology Network to discuss the results of their longitudinal study, “A Panel of Biomarkers Associates With Increased Risk for Cardiovascular Events in Women With Systemic Lupus Erythematosus.”

Rheumatology Network sat down with Liana Fraenkel, MD, MPH, the lead investigator for the study: OPEX: Development of a novel overall patient experience measure to facilitate interpretation of comparison effectiveness studies. In partnership with CreakyJoints, Fraenkel is a rheumatologist at Berkshire Medical Center and Director of Patient Centered Population Health Research.

Rheumatology Network sat down for an interview with Benjamin Nowell, PhD, in partnership with CreakyJoints, to discuss his 2 most recent studies. Nowell is the Director of Patient-Centered Research at CreakyJoints, part of the Global Healthy Living Foundation.

Rheumatology Network sat down for an interview with Glenn Haugeberg, MD, PhD, from Sørlandet Hospital, in Norway, to discuss his presentations for the Rheumatology Winter Clinical Symposium. He will be presenting his findings on Biosimilars: Review and Real-World Experience and Osteoimmunology: Osteoporosis and Beyond.

Rheumatology Network interviewed Roy Fleischmann, MD, to discuss his presentations for the Rheumatology Winter Clinical Symposium. He is presenting his findings on Combination Therapy in Rheumatology and Rheumatology 2020: A Year in Review of Novel Therapies.

This week we sat down for an interview with Arthur Kavanaugh, MD, to discuss his presentations for the Rheumatology Winter Clinical Symposium. He is currently the chairman for the 2021 conference. Kavanaugh is Professor of Medicine and Director of the Center for Innovative Therapy at UC San Diego. He will be presenting his findings on Rheumatology 2020: A Year in Review for rheumatoid arthritis, spondylarthritis, and psoriatic arthritis. We discuss what sets RWCS apart from other conferences and the exciting content that participants can expect.
